Endo Follows Opioid Bankruptcy Playbook, With A Few Twists (1)

Endo International Plc’s bankruptcy filing follows other big pharma companies into Chapter 11 to manage liability from the nation’s opioid crisis, but contains some distinctions from other notable mass tort litigation bankruptcies.

Endo’s Chapter 11 case proposes to pay up to $550 million to opioid victims by shepherding thousands of victim claims in bankruptcy court, similar to how Purdue Pharma LP and Mallinckrodt Plc treated claims in their bankruptcies.

The Dublin-based drug manufacturer, which reported $3 billion in revenue in 2021, filed for bankruptcy Tuesday with $8 billion in debt. It has proposed a sale plan that would allow a ...